TIM-3 expression in human osteosarcoma: Correlation with the expression of epithelial‑mesenchymal transition-specific biomarkers

Shang,Yongjun; Li,Zhanyong; Li,Hong; Xia,Haibo; Lin,Zhenhua

doi:10.3892/ol.2013.1410

TIM-3 expression in human osteosarcoma: Correlation with the expression of epithelial‑mesenchymal transition-specific biomarkers

Authors:
- Yongjun Shang
- Zhanyong Li
- Hong Li
- Haibo Xia
- Zhenhua Lin
View Affiliations

Affiliations: Department of Pathology and Cancer Research Center, Yanbian University Medical College, Yanji, Jilin 133002, P.R. China, Department of Orthopedics, Affiliated Hospital of Chifeng University, Chifeng, Inner Mongolia 024000, P.R. China, Department of Otorhinolaryngology and Head-Neck Surgery, Xinqiao Hospital, PLA Third Military Medical University, Chongqing 400037, P.R. China
Published online on: June 18, 2013 https://doi.org/10.3892/ol.2013.1410
Pages: 490-494

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Signals from the T cell Ig- and mucin-domain-containing molecules (TIMs) have been demonstrated to be actively involved in regulating the progression of carcinomas. However, the expression and distribution of these molecules in osteosarcoma, the most common primary bone malignancy with poor prognosis, have not been investigated. In this study, the expression of TIMs was examined in nine invasive human osteosarcomas using immunohistochemistry, and the phenotypes were detected by dual immunofluorescence staining. Using immunohistochemistry, it was observed that only TIM-3, rather than TIM-1 or TIM-4, was expressed in these tumor specimens, where it was localized in the cytoplasm and plasma membrane of tumor cells. Dual immunofluorescence staining revealed that the expression of TIM-3 was observed in all cell types investigated, including CD68+ macrophages, CD31+ endothelial cells, CK-18+ epithelial cells and PCNA+ tumor cells. Notably, in sarcoma cells, TIM-3 was co-expressed with certain biomarkers of epithelial-mesenchymal transition (EMT), including vimentin, Slug, Snail and Smad. These combined results suggest that TIM-3 triggers tumor cells to acquire features of aggressive EMT and may be involved in the pathogenesis of this malignancy.

View Figures

View References

1.	Szuhai K, Cleton-Jansen AM, Hogendoorn PC and Bovée JV: Molecular pathology and its diagnostic use in bone tumors. Cancer Genet. 205:193–204. 2012. View Article : Google Scholar : PubMed/NCBI
2.	Kuchroo VK, Dardalhon V, Xiao S and Anderson AC: New roles for TIM family members in immune regulation. Nat Rev Immunol. 8:577–580. 2008. View Article : Google Scholar : PubMed/NCBI
3.	Kuchroo VK, Umetsu DT, DeKruyff RH and Freeman GJ: The TIM gene family: emerging roles in immunity and disease. Nat Rev Immunol. 3:454–462. 2003. View Article : Google Scholar : PubMed/NCBI
4.	Sonar SS, Hsu YM, Conrad ML, et al: Antagonism of TIM-1 blocks the development of disease in a humanized mouse model of allergic asthma. J Clin Invest. 120:2767–2781. 2010. View Article : Google Scholar : PubMed/NCBI
5.	de Souza AJ, Oriss TB, O’malley KJ, Ray A and Kane LP: T cell Ig and mucin 1 (TIM-1) is expressed on in vivo-activated T cells and provides a costimulatory signal for T cell activation. Proc Natl Acad Sci USA. 102:17113–17118. 2005.PubMed/NCBI
6.	Rodriguez-Manzanet R, Sanjuan MA, Wu HY, et al: T and B cell hyperactivity and autoimmunity associated with niche-specific defects in apoptotic body clearance in TIM-4-deficient mice. Proc Natl Acad Sci USA. 107:8706–8711. 2010. View Article : Google Scholar : PubMed/NCBI
7.	Monney L, Sabatos CA, Gaglia JL, et al: Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease. Nature. 415:536–541. 2002. View Article : Google Scholar : PubMed/NCBI
8.	Sakuishi K, Apetoh L, Sullivan JM, Blazar BR, Kuchroo VK and Anderson AC: Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med. 207:2187–2194. 2010. View Article : Google Scholar : PubMed/NCBI
9.	Freeman GJ, Casasnovas JM, Umetsu DT and DeKruyff RH: TIM genes: a family of cell surface phosphatidylserine receptors that regulate innate and adaptive immunity. Immunol Rev. 235:172–189. 2010.PubMed/NCBI
10.	Zhuang X, Zhang X, Xia X, et al: Ectopic expression of TIM-3 in lung cancers: a potential independent prognostic factor for patients with NSCLC. Am J Clin Pathol. 137:978–985. 2012. View Article : Google Scholar : PubMed/NCBI
11.	Li H, Wu K, Tao K, et al: Tim-3/galectin-9 signaling pathway mediates T-cell dysfunction and predicts poor prognosis in patients with hepatitis B virus-associated hepatocellular carcinoma. Hepatology. 56:1342–1351. 2012. View Article : Google Scholar : PubMed/NCBI
12.	Dorfman DM, Hornick JL, Shahsafaei A and Freeman GJ: The phosphatidylserine receptors, T cell immunoglobulin mucin proteins 3 and 4, are markers of histiocytic sarcoma and other histiocytic and dendritic cell neoplasms. Hum Pathol. 41:1486–1494. 2010. View Article : Google Scholar : PubMed/NCBI
13.	Yang ZZ, Grote DM, Ziesmer SC, et al: IL-12 upregulates TIM-3 expression and induces T cell exhaustion in patients with follicular B cell non-Hodgkin lymphoma. J Clin Invest. 122:1271–1282. 2012. View Article : Google Scholar : PubMed/NCBI
14.	Baghdadi M, Nagao H, Yoshiyama H, Akiba H, Yagita H, Dosaka-Akita H and Jinushi M: Combined blockade of TIM-3 and TIM-4 augments cancer vaccine efficacy against established melanomas. Cancer Immunol Immunother. 62:629–637. 2013. View Article : Google Scholar : PubMed/NCBI
15.	Lim J and Thiery JP: Epithelial-mesenchymal transitions: insights from development. Development. 139:3471–3486. 2012. View Article : Google Scholar : PubMed/NCBI
16.	Wu CY, Tsai YP, Wu MZ, Teng SC and Wu KJ: Epigenetic reprogramming and post-transcriptional regulation during the epithelial-mesenchymal transition. Trends Genet. 28:454–463. 2012. View Article : Google Scholar : PubMed/NCBI
17.	Fernandez IE and Eickelberg O: The impact of TGF-β on lung fibrosis: from targeting to biomarkers. Proc Am Thorac Soc. 9:111–116. 2012.
18.	Hermeking H: MicroRNAs in the p53 network: micromanagement of tumour suppression. Nat Rev Cancer. 12:613–626. 2012. View Article : Google Scholar : PubMed/NCBI
19.	Gao D, Vahdat LT, Wong S, Chang JC and Mittal V: Microenvironmental regulation of epithelial-mesenchymal transitions in cancer. Cancer Res. 72:4883–4889. 2012. View Article : Google Scholar : PubMed/NCBI
20.	Rangel MC, Karasawa H, Castro NP, Nagaoka T, Salomon DS and Bianco C: Role of Cripto-1 during epithelial-to-mesenchymal transition in development and cancer. Am J Pathol. 180:2188–2200. 2012. View Article : Google Scholar : PubMed/NCBI
21.	Hamilton DH, Litzinger MT, Fernando RI, Huang B and Palena C: Cancer vaccines targeting the epithelial-mesenchymal transition: tissue distribution of brachyury and other drivers of the mesenchymal-like phenotype of carcinomas. Semin Oncol. 39:358–366. 2012. View Article : Google Scholar
22.	Li H, Wang C, Guo G, Gao C, Wu Y and Chen Y: The characteristic expression of B7-associated proteins in Langerhans cell sarcoma. Acta Histochem. 114:733–743. 2012. View Article : Google Scholar : PubMed/NCBI
23.	Guo Y, Zi X, Koontz Z, Kim A, Xie J, Gorlick R, Holcombe RF and Hoang BH: Blocking Wnt/LRP5 signaling by a soluble receptor modulates the epithelial to mesenchymal transition and suppresses met and metalloproteinases in osteosarcoma Saos-2 cells. J Orthop Res. 25:964–971. 2007. View Article : Google Scholar : PubMed/NCBI
24.	Niinaka Y, Harada K, Fujimuro M, et al: Silencing of autocrine motility factor induces mesenchymal-to-epithelial transition and suppression of osteosarcoma pulmonary metastasis. Cancer Res. 70:9483–9493. 2010. View Article : Google Scholar : PubMed/NCBI
25.	Sarsilmaz A, Argin M, Sezak M, Altay C and Erdogan N: Primary osteosarcoma arising from subcutaneous tissue: 5-year follow-up. Clin Imaging. 36:402–405. 2012.PubMed/NCBI
26.	Eyre R, Feltbower RG, James PW, Blakey K, Mubwandarikwa E, Forman D, McKinney PA, Pearce MS and McNally RJ: The epidemiology of bone cancer in 0–39 year olds in northern England, 1981–2002. BMC Cancer. 10:3572010.
27.	Andrews EB, Gilsenan AW, Midkiff K, Sherrill B, Wu Y, Mann BH and Masica D: The US postmarketing surveillance study of adult osteosarcoma and teriparatide: Study design and findings from the first 7 years. J Bone Miner Res. 27:2429–2437. 2012.
28.	Mavrogenis AF, Rossi G, Palmerini E, et al: Palliative treatments for advanced osteosarcoma. J BUON. 17:436–445. 2012.
29.	McConkey DJ, Choi W, Marquis L, et al: Role of epithelial-to-mesenchymal transition (EMT) in drug sensitivity and metastasis in bladder cancer. Cancer Metastasis Rev. 28:335–344. 2009. View Article : Google Scholar : PubMed/NCBI
30.	Dunning NL, Laversin SA, Miles AK and Rees RC: Immunotherapy of prostate cancer: should we be targeting stem cells and EMT? Cancer Immunol Immunother. 60:1181–1193. 2011. View Article : Google Scholar : PubMed/NCBI